<DOC>
	<DOCNO>NCT02015546</DOCNO>
	<brief_summary>This 8-week , randomize , double blind , parallel group , 3-arm trial compare 10 mg/day , 20 mg/day 40 mg/day start dos vilazodone follow switch generic SSRIs SNRIs . Vilazodone HCl trade name Viibryd™ approve U.S. FDA treatment major depressive disorder adult . The purpose study evaluate efficacy ( well drug work ) , safety ( side effect ) , tolerability ( well tolerate ) Vilazodone prevent relapse recurrence depression . As vilazodone approve United States Food Drug Administration ( FDA ) prevent recurrence depression , purpose study consider investigational . The word `` investigational '' mean study drug still test research study approve use FDA .</brief_summary>
	<brief_title>Switching From Generic Selective Serotonin Reuptake Inhibitors ( SSRIs ) Selective Serotonin Norepinephrine Reuptake Inhibitors ( SNRIs ) Three Different Dose Initiation Strategies With Vilazodone</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Serotonin</mesh_term>
	<mesh_term>Vilazodone Hydrochloride</mesh_term>
	<mesh_term>Norepinephrine</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<mesh_term>Serotonin Noradrenaline Reuptake Inhibitors</mesh_term>
	<criteria>1 . Age 1865 year inclusive 2 . DSMIV Diagnosis major depressive disorder 3 . If female , nonpregnant/nonlactating 4 . If sexually active female reproductive potential , must use adequate contraception ( i.e. , oral contraceptive , barrier protection , prior tubal ligation ) 5 . Inadequate response antidepressant : score ≥14 17item HAMD CGIS score ≥ 3 retrospective confirmation adequate trial single antidepressant ( define 6week trial acceptable therapeutic dose [ 40 mg fluoxetine , paroxetine 30 mg citalopram , 20 mg escitalopram , 37.5 mg paroxetine CR , 150 mg sertraline , 100 mg fluvoxamine , 225 mg venlafaxine XR ) 6 . Lack tolerability antidepressant : Patient report side effect judge clinically meaningful investigator 7 . HAMD item 2 score ≥ 2 screen 8 . Duration current MDD ≥ 4 week &lt; 24 month 1 . Any Axis I disorder within previous six month screen except Generalized Anxiety Disorder , Social Anxiety Disorder , Panic Disorder Simple Phobias 2 . MDD postpartum onset , psychotic feature seasonal feature 3 . DSMIV substance abuse dependence previous 6 month 4 . Medically unstable judged study investigator clinical and/or laboratory finding 5 . Lack capacity provide inform , write , consent investigator 6 . Previous intolerance vilazodone current use vilazodone screen within 3 month study entry 7 . Significant suicide risk judge investigator base information collect Columbia Suicide Severity Rating Scale ( CSSRS ) 8 . History augmentation atypical antipsychotic , lithium , T3 another antidepressant within 3 month screen 9 . Failure ≥ 3 adequate trial different antidepressant current episode MDD 10 . Concomitant medication : All medication pre exist medical condition permit continue unchanged provide subject stable dose least 12 week . Subjects concomitant mood stabilizer atypical antipsychotic require 2week washout prior screen visit . Subjects minimum 3 month stable dose hypnotic ( e.g . zolpidem 10 mg per day benzodiazepine dose ≤ 2 mg per day lorazepam trazodone ≤ 100 mg per day quetiapine ≤ 100 mg per day ) allow continue hypnotic medication dose . Quetiapine dos ≤ 100 mg per day appropriate hypnotic effect . Over counter medication permit opinion investigator , consider significant impact study . Any medication potential cause clinical significant drug interaction vilazodone judgment investigator require washout .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Vilazodone</keyword>
</DOC>